Results. We found that synovial fibroblast arthritogenicity was reflected in distinct dynamic patterns of transcriptional dysregulation, which was especially enriched in pathways of the innate immune response and mesenchymal differentiation. A functionally representative subset of these changes was associated with methylation, mostly in gene bodies. The arthritogenic state involved highly active promoters, which were marked by histone H3K4 trimethylation. There was significant overlap between the mouse and human data at the level of dysregulated genes and to an even greater extent at the level of pathways.
Conclusion. This study is the first systematic examination of the pathogenic changes that occur in mouse synovial fibroblasts during progressive TNFdriven arthritogenesis. Significant correlations with the respective human RA synovial fibroblast data further validate the human TNF-transgenic mouse as a reliable model of the human disease. The resource of data generated in this work may serve as a framework for the discovery of novel pathogenic mechanisms and disease biomarkers.
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by extensive damage to diarthrodial joints. Our understanding of RA has largely relied on the use of mouse models, such as collageninduced arthritis, collagen antibody-induced arthritis, and the tumor necrosis factor (TNF)-transgenic animal models. Work on the latter models established the proof of principle for the pivotal role of TNF in disease pathogenesis and its therapeutic targeting by anti-TNF biologic drugs (1) . The same models established the synovial fibroblast as a key cellular player and target of TNF in RA (2) . Whereas under physiologic conditions, synovial fibroblasts provide nourishment and protection for the joint, upon chronic innate immune activation, the fibroblasts undergo a complex process that has been referred to as arthritogenic "transformation." That is, they proliferate aberrantly and acquire resistance to death, thus becoming hyperplastic, and they express proinflammatory cytokines, matrix-degrading enzymes, and cell adhesion molecules, thus contributing to an inflammatory and tissue-damaging microenvironment (3) (4) (5) . Synovial fibroblasts can also migrate to distant sites via the vasculature, maintaining and transferring their newly acquired destructive properties, both in humans and in mouse models (6, 7) .
Epigenetic changes underlie the activated and aggressive phenotype of RA synovial fibroblasts (8) . Most of the relevant studies have examined the contribution of the methylome, reporting global genomic hypomethylation in the arthritogenic human synovial fibroblast (9) (10) (11) (12) . In addition, microRNA dysregulations are known to accompany both human and murine diseases (13) .
In order to assess the gene expression and epigenetic changes that occur in synovial fibroblasts during the arthritogenic process, we used next-generation sequencing (NGS) approaches to initiate a multilevel omics analysis of human TNF-transgenic (Tg197) mouse synovial fibroblasts. We report the molecular profile of the activated synovial fibroblasts at the level of the transcriptome, the methylome, and active chromatin, as evidenced by histone H3K4 trimethylation. This profile entails distinct dysregulations associated with functional pathways (notably, those related to the innate immune response and mesenchymal differentiation), methylation changes that correlated with expression in specific genes, and an activated chromatin profile. In the context of this key pathogenic cell type, the human TNF-transgenic mouse model data aligned significantly with the human data, both at the level of the genes and even more so at the level of the pathways.
MATERIALS AND METHODS
Mouse and human synovial fibroblasts. Mouse synovial fibroblasts were isolated from CBAxC57BL/6 human TNFtransgenic (Tg197) mice (1) and their wild-type littermates at 3 disease stages: early (3 weeks), established (8 weeks), and late (11 weeks), as previously described (14) . All mice were housed under specific pathogen-free conditions. Three biologic replicates were isolated per experimental condition, and for each condition, a mixed-sex pool of 3 mice was used. Purity of all isolations was assessed by fluorescence-activated cell sorting, with the following acceptance criteria: .85% positive for CD90.2 and ,2.5% positive for CD45.
Human synovial fibroblast samples used for RNA sequencing were isolated from the knees of 3 RA patients and 3 healthy individuals (as defined below), as described in detail elsewhere (15) . Human RA synovial fibroblasts used for validation assessments were isolated from synovial tissues obtained from patients undergoing joint replacement surgery at the Schulthess Clinic (Zurich, Switzerland). All patients fulfilled the American College of Rheumatology/European League Against Rheumatism 2010 criteria for the classification of RA (16) Human studies were approved by the local ethics committees of the University Hospital Zurich, Switzerland, and the University of Birmingham, Birmingham, UK. Informed consent was obtained from all study subjects.
Extraction of RNA and DNA. RNA was extracted from mouse synovial fibroblasts with the use of an Absolutely RNA Miniprep kit (Agilent Technologies) and from human synovial fibroblasts with use of a miRNeasy Mini kit (Qiagen). DNA was extracted from mouse synovial fibroblasts using a PureLink Genomic DNA Mini kit (Invitrogen).
Enrichment for MethylCap and H3K4me3. A MethylMiner DNA enrichment kit (Invitrogen) was used to enrich for methylated DNA according to the manufacturer's instructions. DNA was first fragmented by sonication to an average size of 250 bp with the use of a Covaris S220 focused ultrasonicator. Enrichment was performed with a double elution (high and low salt) in order to capture both sparsely methylated and densely methylated DNA. The fractions were then combined. To enrich for H3K4me3, DNA was processed using an iDeal ChIP-Seq kit in combination with a ChIP-grade H3K4me3 antibody (both from Diagenode) according to the manufacturer's instructions. Chromatin was first sheared by sonication using a Bioruptor (Diagenode) and then subjected to the H3K4me3 enrichment protocol, with a minor modification: after performing RNase I digestion for 30 minutes at 378C, the de-crosslinked DNA was eluted using a QIAquick polymerase chain reaction (PCR) purification kit (Qiagen). Enrichment (as compared to nonenriched input control) was confirmed by quantitative PCR.
Library preparations and next-generation sequencing. All library preparations, next-generation sequencing, and quality control steps were performed at the McGill University and Genome Quebec Innovation Centre (Montreal, Quebec, Canada). More specifically, for RNA-Seq, TruSeq RNA libraries were prepared and samples were run on an Illumina HiSeq2000 platform using a 100-bp paired-end setup. For MethylCap-Seq, TruSeq genomic DNA libraries were prepared and samples were run in an Illumina HiSeq platform using a 100-bp paired-end setup. For ChIP-Seq, TruSeq genomic DNA libraries were prepared and samples were run in an Illumina HiSeq platform using a 100-bp paired-end setup. For human samples, preparation of libraries and next-generation sequencing were performed as detailed elsewhere (15) .
Bioinformatic analyses. General. Quality of sequencing was accessed using FastQC software (17) , which also Figure 1 . Dysregulation of arthritogenic synovial fibroblasts at the level of the transcriptome across disease stages in the human tumor necrosis factor-transgenic (Tg197) mouse model of rheumatoid arthritis. The RNA-Seq profiles of synovial fibroblasts from Tg197 mice and wild-type controls were compared for the 3 disease stages: early (3 weeks), established (8 weeks), and late (11 weeks). A, Volcano plots depicting differentially expressed genes (DEGs; significantly down-regulated, no change, or significantly up-regulated) at the 3 disease stages. B, Venn diagrams showing overlap of significant DEGs among the disease stages. C, Heatmap showing clustering of significant DEGs across disease stages (left). Genes were found to categorize into 6 clusters, each with a distinct pattern of dysregulation (right). Functional analysis was performed on the clusters, and descriptors summarizing the top 10 gene ontology biologic process (GO-BP) terms (ranked by q value) were illustrated with the heatmap. D, Heatmap showing clustering of the top 25 significant GO-BP terms (ranked by q value) associated with each disease stage. E, Common transcriptional network of the 3 disease stages, as identified with the Regulatory Network Enrichment Analysis tool. Color bar indicates node centrality; circle size indicates the number of edges from the node (i.e., the number of targets). FC 5 fold change; PV 5 corrected P value; ECM 5 extracellular matrix.
calculates the average quality of reads. The number of mapped reads was calculated with the use of the SAMtools tool (-flagstat) (18) . Conversion of alignment files (bam) to bed format was done with BEDTools (bamtobed) (19) . BAM files were also converted to bedgraph with BEDTools (genomecov -bga) and bedgraph files were converted to bigwig using the UCSC bedGraphToBigWig utility. Volcano plots were created in R with an in-house developed script, which is based on the ggplot package. Heatmaps were also generated in R with the heatmap.2 function of the gplots package. Functional analyses were performed with the online tool Enrichr (20) . For all statistical comparisons, the cut-off for significance was set to 0.05. With the exception of KEGG pathway enrichment and human RNA-Seq analyses, in all other comparisons P values were adjusted for multiple comparisons. Human-mouse overlap was tested using an online tool based on a normal approximation to the exact hypergeometric probability (21) .
RNA-Seq. Mouse RNA-Seq samples were analyzed with the TopHat-Cufflinks pipeline (22) (23) (24) . Reads were mapped to the mm9 genome with TopHat2. Transcripts were assembled using Cufflinks. Final transcriptome assembly was performed with cuffmerge, and differential expression was identified with cuffdiff. Venn diagrams were created with InteractiVenn (25) or with the online tool Venny (26) . Clustering of genes was performed using K-means, based on both the fold change and the q value for all time points. The number of clusters was selected with the use of the elbow rule. The average cluster profile was plotted in R using the fold changes and the q values for the clusters' centroids. Regulatory Network Enrichment Analysis (RNEA) was performed as previously described (27) . Networks were visualized in Cytoscape (28) , and the characteristics of nodes (color and size) were based on betweenness centrality and outdegree. Compilation of the lists of differentially expressed genes from the human RNA sequencing data has been described elsewhere (15) .
MethylCap-Seq and H3K4me3-Seq. The MethylCapSeq and H3K4me3-Seq reads were mapped using the BWA tool (29) . Visualizations of general profiles were created with seqplots (30) . Methylation plots were generated with the use of a pseudo-length of 10 kb, to which the genes were extended or shrunk using linear approximation ("anchored features"). Differential analysis was performed with diffReps (31) using the default normalization procedure and windows of 500 bases for MethylCap-Seq and 1,000 bases for H3K4me3-Seq.
Quantitative reverse transcription-PCR (RT-PCR). For validation of dysregulated genes identified by RNA-Seq in the mouse, an independent set of mouse synovial fibroblast RNA was used, comprising triplicate biologic samples for each condition. All primers were purchased as QuantiTect Primer Assays (Qiagen) and were used in conjunction with a QuantiFast SYBR Green RT-PCR kit (Qiagen) according to For validations in human synovial fibroblasts, reversetranscribed total RNA was measured in an Applied Biosystems 7500 Real-Time PCR system using self-designed primers (Supplementary Table 2 , available at http://onlinelibrary. wiley.com/doi/10.1002/art.40128/abstract) in combination with SYBR Green dye. As controls, we used no-template control samples, dissociation curves, and samples containing the nontranscribed RNA. Expression of hypoxanthine guanine phosphoribosyltransferase1 (HPRT1) was used for normalization according to the following formula: DC t 5 (target expression -HPRT1 expression).
Data availability. The data have been deposited in the Gene Expression Omnibus database under the following accession numbers: GSE95251, GSE95252, GSE95254, and GSE95256.
RESULTS
Distinct patterns of transcriptional dysregulation during disease progression in arthritogenic synovial fibroblasts from Tg197 mice. In order to explore cell-specific transcriptional changes accompanying disease progression in the Tg197 mouse model of RA, synovial fibroblasts were isolated from diseased and healthy animals at 3 different stages: 3 weeks (early stage of not overtly manifested pathologic changes), 8 weeks (established disease), and 11 weeks (late stage of severe pathologic changes) (see Supplementary Figures 1 and  2A , available at http://onlinelibrary.wiley.com/doi/10.1002/ art.40128/abstract). RNA samples were processed for NGS, and the quality of sequencing was confirmed (Supplementary Figures 2B and C). As can be seen in Figure  1A , more than 1,000 significant differentially expressed genes (DEGs) were identified. The early stage of disease was characterized by the fewest DEGs, which were equally represented by up-regulation and down-regulation, whereas the most DEGs were identified during the established disease stage, where up-regulation predominated. This was also true for the late stage of disease. A considerable number of DEGs persisted throughout the disease stages (177 up-regulated and 114 down-regulated), while some were also stage-specific ( Figure 1B) . Interestingly, the vast majority of early DEGs were seen throughout the disease stages, indicating that these genes were ones that play a central role in disease development.
To further explore the identified patterns of dysregulation, we classified DEGs into 6 clusters according to their occurrence during disease progression ( Figure  1C ). Three clusters were associated with up-regulated genes and 3 with down-regulated genes. These clusters were then subjected to functional enrichment analysis to examine whether they were associated with distinct functional categories. With regard to up-regulation clusters, immune response was identified as the most prominent functional category, being significant throughout disease progression. Stage-specific up-regulation encompassed functions of cell signaling, cell adhesion, cytokine response, cell motility, and the extracellular matrix. Notably, genes that were downregulated during all disease stages were functionally related to differentiation. This became more pronounced in the cluster of genes that were downregulated during the late stage, where we observed a deficit in the culmination of differentiation processes (termed morphogenesis). Additional functions of downregulation across disease stages were related to the extracellular matrix and negative regulation of proliferation (hence an overall positive proliferative potential). Stage-specific down-regulation clusters included functions of cell division and regulation of Wnt signaling. In the context of all of these clusters, late was the most distant hierarchically, indicating the farthest, functionally evolved stage of disease.
In a complementary functional approach, the dysregulation of each disease stage was subjected to functional enrichment, and clustering was performed according to the top 25 terms of the early stage ( Figure  1D ). Functions enriched in up-regulated genes mostly corresponded to the immune response, and their enrichment became more pronounced with disease progression. The majority of the top immune response-related ontology terms enriched during the 3 disease stages were related to the innate immune response and Tolllike receptor (TLR) signaling. Functions enriched in down-regulated genes were mostly linked to differentiation and the extracellular matrix; the tendency across disease stages applied here too, albeit to a lesser extent. As with the first functional analysis, the late stage of disease was the most distant one.
We additionally sought to identify transcriptional regulators that underlie the identified dysregulation profiles. To this end, we used RNEA, a tool developed in-house that performs enrichment analysis using transcriptome data in combination with transcriptional network assignment algorithms (27) . Having observed that despite the high complexity of networks derived for each disease stage, the top significant central players were consistent (Supplementary Figure 3 , available at http://onlinelibrary.wiley.com/doi/10.1002/art.40128/ abstract), we focused on the common transcriptional network that applied throughout disease. As can be seen in Figure 1E our analysis as having both a central and strong impact, placing the NF-kB and mesenchymal differentiation pathways at the core of our transcriptome profiles and thus at the core of Tg197 pathogenesis. Association of global DNA methylation changes with the activated Tg197 synovial fibroblast profile. We next examined the methylome of the arthritogenic synovial fibroblast. MethylCap sequencing was performed using the same set of biologic samples. Quality control metrics are shown in Supplementary Figures 2B and C (available at http://onlinelibrary.wiley.com/doi/ 10.1002/art.40128/abstract). Approaching differential methylation with the use of a promoter/gene body dichotomy in our analyses, we observed that in the promoters of the early and late stages, differentially methylated regions (DMRs) showed similar levels of enrichment (hypermethylation) and depletion (hypomethylation) (Figure 2A ). In the established disease stage, there was a tendency for more hypermethylation. With regard to gene body methylation, there was pronounced hypomethylation associated with the established stage of disease. Upon examining the distribution of these DNA methylation changes, we found that as disease progressed, the signal tended to spread away from the transcription start site ( Figure 2B ). There was greater enrichment in gene body methylation, most of which was exonic, while most of the overall differential methylation was found in CpG islands.
With regard to the relationship between DNA methylation and expression, we first noted that if we stratified our expression data into quantiles, then methylation appeared to be an indicator of the level of expression, with positive expression downstream of the transcription start site and mostly negative expression upstream of it ( Figure 2C ). In our attempt to correlate the dysregulations identified at the RNA level with the changes in DNA methylation, we observed that approximately one-fourth of the DEGs at any disease stage were accompanied by a change in methylation ( Figure 2D ). Of these, approximately one-half followed the "canonical" correlation between methylation and expression (inverse for the promoter and positive for the gene body), the vast majority of which corresponded to gene body DMRs. Approximately one-fifth of the latter genes (i.e., those whose dysregulation at the RNA level correlated positively with gene body methylation) were associated with exonic DMRs.
We then confined our analysis to the genes that were both differentially expressed and methylated in the expected manner and performed functional enrichment. This approach returned functions that were most significantly related to the extracellular matrix during all disease stages and were significantly related to cytokine signaling, proliferation, adhesion, migration, differentiation, and cell death during the established and late disease stages. These enrichments constituted a representative subset of the above-described functional profile based on the RNA-Seq data.
These results suggest that DNA methylation accompanies a subset of functionally important, diseaseassociated dysregulated genes in the Tg197 mouse.
Open chromatin as a mark of synovial fibroblast activation. To assess transcriptionally active genes, we probed for H3K4 trimethylation, a histone mark associated with active promoters. Quality control metrics of the sequencing are shown in Supplementary Figure 2 . Most differentially marked regions were identified at the early time point, when H3K4me3 depletion predominated, whereas at the other 2 time points, there were approximately equal numbers of enriched and depleted regions ( Figure 3A) . Upon inspecting the distribution of changes, we observed that at all 3 time points, there was enrichment in the promoter, as expected for this histone mark, without any clear differences in distance from the transcription start site ( Figure 3B ). Focusing therefore around the transcription start site, we noted that H3K4me3 signal mirrored the level of expression of genes from both Tg197 mice and wild-type mice ( Figure  3C ). Interestingly, the activated state of the arthritic synovial fibroblast was evident in this marker of open chromatin during both the early and the established disease stages, as H3K4 trimethylation levels in the Tg197 mouse were higher overall.
Significant H3K4 trimethylation in synovial fibroblasts was hence found to be a good predictor of differential expression. The correlation between H3K4me3 and RNA expression was high for all disease stages (r s 5 0.69 for early, 0.61 for established, and 0.72 for late stages) ( Figure 3D ). Due to this high correlation, the output of functional enrichment analysis of differentially H3K4-marked and differentially expressed genes mirrors that of the general profile (data not shown).
Based on the above findings, pathogenic activation of the synovial fibroblast is engraved on its chromatin, with H3K4 trimethylation being a good marker of this activation.
Assessment of the impact of exogenously administered TNF on the identified signatures. TNF plays a pivotal role in RA, both in the Tg197 mouse model and in humans, where it is a major pathogenic cytokine in the inflammatory milieu of the arthritic joint (1). We assessed the ex vivo impact of TNF at the level of the transcriptome, the methylome, and the active 1594 NTOUGKOS ET AL chromatin to build on our understanding of the interplay of TNF and synovial fibroblast biology, given that TNF stimulation is widely used in studies of human RA synovial fibroblasts. To this end, synovial fibroblasts from wild-type mice were treated with human TNF for 24 hours and analyzed in parallel with our above studies (see Supplementary Figure 1 for sequencing metrics). . Pronounced contribution of tumor necrosis factor (TNF) to the signatures identified in synovial fibroblasts from human TNF-transgenic (Tg197) mice. RNA-Seq, MethylCap-Seq, and H3K4me3-Seq were performed in wild-type mouse synovial fibroblasts that had been treated for 24 hours with 10 ng/ml of human TNF, and the results were compared to those in untreated controls. A, Volcano plots depicting changes induced by TNF at the level of the transcriptome, methylome, and active chromatin. B, Venn diagrams showing overlap of significant dysregulations at the level of genes (RNA) and regions (DNA methylation and H3K4 trimethylation) as well as at the level of the KEGG pathways (RNA) among the 3 disease stages in Tg197 mice and upon treatment with human TNF. FC 5 fold change; PV 5 corrected P value.
At the level of differentially expressed genes or differentially marked regions, a considerable number of dysregulations forming part of the Tg197 mouse signature were found to be shared with the TNF-induced profiles at all 3 disease stages: ;85% for RNA and DNA methylation and 70% for H3K4 trimethylation ( Figure 4B ). At the level of the pathways, the overlap became more pronounced: we found that 16 of the 20 KEGG pathways that were enriched in wild-type synovial fibroblasts following TNF stimulation were also found to be enriched in the Tg197 signatures. Nonetheless, high numbers of significant DEGs (100 early stage, 718 established, and 554 late stage) and enriched pathways (1, 18, and 18, respectively) were identified only in the Tg197 profiles.
It follows from the above that as ex vivo, so in vivo: TNF sensed by the synovial fibroblast contributes to the creation of a proinflammatory and pathogenic environment that is reflected, at the level of both genes and pathways, in pathogenic changes to the transcriptome, the methylome, and chromatin.
Validation of sequencing results and comparison with data in humans. In a technical validation of our sequencing results, a panel of 20 genes selected from the top dysregulated ones identified by RNA-Seq were validated by quantitative RT-PCR, using an independent sample set. As can be seen in Figure 5A , there was a very high correlation between RNA-Seq and quantitative RT-PCR data, establishing experimental reliability (r s 5 0.96 for early, 0.90 for established, and 0.90 for late disease stages).
To assess whether our findings in the mouse can be verified in the context of human disease, we made use of an RNA-Seq data set comparing human RA synovial fibroblasts to healthy synovial fibroblasts. The broad picture of the human dysregulations we identified is illustrated in Figure 5B . At the level of the gene, approximately one-tenth of mouse synovial fibroblast dysregulations were also identified in the same direction in humans, a very significant overlap (P , 0.001), despite differences in isolation and culturing conditions, interspecies variability, and high interpatient variability in humans ( Figure 5C ). At the level of the pathway, this significant overlap became higher, with approximately onethird of the pathways that were enriched in mouse synovial fibroblasts also being enriched in human synovial fibroblasts (P , 0.001); key pathways identified above, such as innate immune and differentiation pathways, were found to be shared.
Eight genes that were validated in mouse synovial fibroblasts, represent key pathways, such as immune response and differentiation, and were shared by mice and humans were also examined by quantitative RT-PCR in human synovial fibroblasts ( Figure 5D ). Five of them were significantly dysregulated in these samples, namely, MMP3 (up-regulated) as well as LECT1, WNT16, PPARG, and SP7 (down-regulated). NOD2 (an up-regulated DEG) was also found to differ significantly upon TNF stimulation, as its baseline levels were very low in humans (data not shown).
For a comparison of mice and humans at the level of the methylome, we used data from 2 studies of human synovial fibroblasts (9, 10) . We compared the intersection of changes identified in these studies with our mouse methylation data. As can be seen in Figure  5E , approximately one-half of the genes found to be dysregulated in humans were also found in Tg197 mice; this was a highly significant overlap (P , 0.001).
Our findings contribute to a systems-level validation of the human TNF-transgenic mouse as a model of RA in humans, highlighting cell type-specific commonalities in key genes and pathways.
DISCUSSION
In light of recent controversies about whether animal models accurately reflect human disease (32,33), we again examined one of the key mouse models of RA, the human TNF-transgenic mouse, to develop a highresolution profile of the activated synovial fibroblast and compare that to the profile in humans with RA. In this disease-driving cell type, arthritogenicity is mirrored in distinct expression profiles characterized by early onset and persistent changes, indicating that even before the joint has been extensively damaged, pathogenic molecular processes are already at work.
Functionally, continuous up-regulation of gene expression was connected with the innate immune response, emphasizing the role of the synovial fibroblast as an innate immune sensor (34) (35) (36) . Down-regulation was linked to functions related to cell differentiation, with 2 of the 3 central transcriptional regulators identified, namely, Cebpa and Pparg, being involved in mesenchymal differentiation (37, 38) ; the latter was also validated in human RA synovial fibroblasts by quantitative RT-PCR. Given the unclear relationship between mesenchymal stem cells and RA synovial fibroblasts and the importance of differentiation processes in disease pathogenesis (39, 40) , the aspect of synovial fibroblast ontogeny in physiology and pathology merits further exploration and presents a good case for the use of omics data as the starting point for more-focused studies.
To date, the most studied epigenetic change in RA has been DNA methylation. The examination of our data from the perspective of the gene body, which represents the majority of the gene space, reveals a hypomethylated profile, which is consistent with previous reports of studies of human RA synovial fibroblasts (12) . Genomewide correlations between DNA methylation and gene expression are hampered by the complexity of the former as an epigenetic phenomenon. Nevertheless, we have been able to link differential methylation, most abundantly at the level of the gene body, with approximately one-fourth of the expression changes we identified.
In concert with the above-described functional highlights, we also found highly significant examples of 1598 NTOUGKOS ET AL mesenchymal differentiation processes and the innate immune response among the functions enriched in differentially methylated and expressed genes. Sox10, through methylation-dependent transcription, has been implicated as a suppressor of stemness by binding to b-catenin; it is also expressed by a novel rat synovial stem cell population capable of giving rise to mesenchymal lineages (41, 42) . Moreover, this is the first report of the methylation-modulated expression of TLR-2, a known innate immune-sensing receptor in synovial fibroblasts, as observed in other inflammatory conditions (34, 43) . It is also the first time that increased expression of Pdpn, the gene for podoplanin, which is well-documented in the arthritic synovium of humans, has been linked with changes in promoter methylation, similar to other cells of mesenchymal origin (44) (45) (46) . Furthermore, this work represents the first attempt to explore histone H3K4 trimethylation in synovial fibroblasts. Their arthritogenicity was shown to be defined by activated chromatin, making the promoters of pathogenic genes highly active and ready to drive disease-promoting transcription. Interestingly, it is known that in macrophages, another innate immune cell type, TLR signaling induces H3K4 trimethylation so as to facilitate the rapid transcription of target genes (47) . This histone mark has also been reported to play a role in mesenchymal differentiation (48) . Even if genome-wide experiments cannot resolve the causal link between histone modifications and gene expression changes, time-dependent approaches such as the one presented here could provide the basis for more sophisticated models that could be used to address this issue.
Bioinformatic probing of the present Tg197 mouse RNA-Seq data by functional enrichment analysis against the human-specific dbGaP database (49) revealed that the most significant term returned in all 3 disease stages was "rheumatoid arthritis," a finding that, when combined with the overall high similarity between the mouse and human data presented here, reinforces the value of this model. Despite its TNF dependency and the observed overlap between the Tg197 mouse profiles and those identified upon treatment with human TNF, the latter failed to include many gene dysregulations, especially those of the established and late stages of disease. More importantly, the mouse pathways that collectively account for the resemblance to human disease were significantly enriched only in the Tg197 mouse profiles, which highlights the importance of analyses deriving from in vivo contexts.
To our knowledge, this is the first cell typespecific multilevel characterization of a mouse model of RA in alignment with human disease. With our current findings, we posit that, rather than comparing mixed and often secondarily activated material from animal models and humans, careful validation of primarily disease-associated cell types, such as synovial fibroblasts in RA, should be ensured before concluding that an animal model mimics or does not mimic the human disease and the extent to which that occurs. The present compendium of data can serve as the foundation for a range of future studies, from the basic mechanistic investigation of disease pathogenesis to the translational examination of novel biomarkers and from the preclinical testing of therapeutics to the comparative alignment of readouts against reference profiles presented herein.
